Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02580877 · ClinicalTrials.gov registry record · Phase 2
Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT02580877 is a Phase 2 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 92 participants.
The verdict
NCT02580877, a Phase 2 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
The study is a 2 arm, multi-center, randomized, open-labeled clinical trial designed to assess the effects of varying doses and schedules of oral insulin on immunological and metabolic markers in relatives at risk for type 1 diabetes (T1D).
Interventions
- DRUG 67.5 mg oral insulin crystals daily
- DRUG 500mg oral insulin crystals every other week
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2016-01 |
| Est. Completion | 2018-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02580877
The ClinicalTrials.gov registry entry for NCT02580877 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 67.5 mg oral insulin crystals daily is the first listed.
NCT02580877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02580877 about?
NCT02580877 is a clinical study titled "Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)". The study is a 2 arm, multi-center, randomized, open-labeled clinical trial designed to assess the effects of varying doses and schedules of oral insulin on immunological and metabolic markers in relatives at risk for type 1 diabetes (T1D).
What is the current status of trial NCT02580877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2016-01. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02580877?
The interventions under investigation include: 67.5 mg oral insulin crystals daily (DRUG), 500mg oral insulin crystals every other week (DRUG).
Who is sponsoring clinical trial NCT02580877?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.